205-18: Developing Clinical Targets through PET Imaging: Dementia and Depression

4.5 (2 votes)

205-18:  Developing Clinical Targets through PET Imaging: Dementia and Depression

This presentation describes the use of uniquely prepared ligands for PET imaging, which is changing how we understand the neuroscience of addictions.

  Robert Innis, MD, PhD

Disclosures:  NIMH received research support from Janssen Pharmaceuticals to conduct the study of neuroinflammation in depression. The planners have no conflict of interest or commercial support to disclose.  Off-label uses will not be discussed during this presentation.

Session Length:
 1 hour 13 minutes

Target Audience:  RN, APRN

Learning Outcomes:
Upon completion of this presentation, the participant will be able to:

  1. Discuss the science of PET scanning related to treatment of psychiatric disorders.
  2. Relate the use of PET scanning to understanding inflammation in diseases of the brain and associated symptom manifestation. 

Keywords:  Research, Older Adults, Mental Health Conditions

Continuing Nursing Education:
1.25 contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Originally Presented
APNA 16th Annual Clinical Psychopharmacology Institute
Baltimore, Maryland
Saturday, June 9, 2018
4:00pm - 5:30pm

The contact hours for this session expire: December 31, 2020

Components visible upon registration.